Nordson reports Q3 results tomorrow against a backdrop where options traders have abruptly abandoned the defensive posture they held all summer — a shift stark enough to be the standout signal heading into the print.
The options move is dramatic. The put/call ratio collapsed to 0.52 on Tuesday, more than four standard deviations below its 20-day average of 0.90 — the most call-heavy reading in months, and a sharp break from a reading that had been parked between 0.90 and 1.05 for the better part of six weeks. That kind of single-session repricing in the PCR typically reflects either a surge in call buying or a rapid unwinding of put hedges, and either way it signals that options participants moved decisively toward upside exposure the day before results.
Short interest tells a far less charged story, and that contrast matters. Bears have been quietly reducing exposure for weeks — SI has fallen roughly 9% over the past month to 2.9% of the free float, with another 4.5% unwinding in just the past week. The borrow market confirms there is no squeeze dynamic in play: availability is exceptionally loose at around 5,120% of current short interest, with borrowing costs running at just 0.35%, a level that is 43% below where it was a month ago. Positioning here is light and getting lighter, not crowded.
The Street is modestly constructive but not aggressively so. The consensus sits at buy, with a mean price target near $317 — roughly 4% above Tuesday's close of $304. Analysts who updated targets after the May quarter mostly raised them: Oppenheimer moved to $335 and DA Davidson to $345, both maintaining positive ratings. BNP Paribas sits at the cautious end with a $290 neutral. That range — $290 to $345 — neatly frames the bull/bear debate. Bulls point to M&A optionality, rising FY26-27 EPS estimates, and medical and fluid solutions revenue growth. Bears flag margin compression from regulatory adjustments, soft North American semiconductor demand, and end-market cyclicality. Valuation multiples have drifted higher over the past month: the PE has expanded by roughly 1.5 turns to 25.3x, and the EV/EBITDA has edged down slightly to 19.3x, suggesting the market has already given the stock some credit for the recovery.
The two most recent earnings reactions on record both pointed in the same direction — the May quarter produced a 5% next-day gain and a 4.3% five-day gain, while an earlier release delivered a 5.6% one-day move. Neither provided a bearish template. Peers had a rough week: FELE fell 5.4%, IR dropped 5.0%, SWK lost 5.4%, and ESAB shed 10.2%. Nordson's own 2.3% weekly decline looks contained by comparison, which may partly explain the call-buying appetite heading into the release — relative resilience against a weak peer tape.
With earnings hitting tomorrow morning, the sharpness of the PCR move and the consistency of recent post-print rallies are what traders will be watching most closely as the quarter lands.
See the live data behind this article on ORTEX.
Open NDSN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
